Apellis sales numbers show steady demand for new eye drug, despite safety worries

The company says Syfovre prescriptions accelerated again in August after a rocky summer of side effect probes.

By Kristin Jensen • Oct. 5, 2023

Lilly names new diabetes and obesity chief as Mounjaro sales take off

Company veteran Mike Mason, who took leadership of the division four years ago, is retiring and will be replaced by immunology head Patrik Jonsson.

By Jonathan Gardner • Oct. 4, 2023

Explore the Trendline➔

Alzheimer's disease

Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

By BioPharma Dive staff

Moderna claims positive results in early study for combo COVID, flu shot

The company is planning to start a Phase 3 trial of the vaccine this year, and is targeting a regulatory approval in 2025.

By Delilah Alvarado • Oct. 4, 2023

Sandoz spins out of Novartis as standalone generic drugmaker

The spinoff, now complete, is a major step in CEO Vas Narasimhan’s plan to refocus Novartis more tightly around novel prescription drugs and new technologies.

By Kristin Jensen • Oct. 4, 2023

J&J, retreating from infectious disease, partners with Sanofi on E. coli vaccine

The French vaccine giant will pay J&J $175 million to share rights to the experimental inoculation, which is currently in Phase 3 testing.

By Kristin Jensen • Oct. 3, 2023

Lilly to enter radiopharmaceutical drug field with $1.4B Point buyout

Point Biopharma is one of the most advanced in a group of emerging biotechs working on radioligand therapies for cancer.

By Ned Pagliarulo • Oct. 3, 2023

Novartis’ closely watched rare disease drug scores in kidney disorder

Called iptacopan, the experimental medicine has now scored positive results in three late-stage clinical trials, the latest in an uncommon kidney disorder known as IgA nephropathy.

By Jacob Bell • Oct. 2, 2023

Ready for open source in life sciences? Your pharma analytics journey might be

It’s time to adopt open-source technology – but not without security, compliance and guardrails.

By Mark Lambrecht, Senior Director, Health and Life Sciences Practice • Oct. 2, 2023

Novo Nordisk, Evotec partner in metabolic disease drug discovery pact

Hunting for more metabolic disease drugs, Novo plans to work with Evotec to shape early academic research into new development programs.

By Gwendolyn Wu • Sept. 26, 2023

Novartis radiopharmaceutical drug succeeds in first-line gut cancer study

Novartis has made a large investment in targeted radiotherapies, sparking competition from fellow pharma companies and young biotechs.

By Jonathan Gardner • Sept. 25, 2023

Eisai’s Alzheimer’s drug Leqembi approved in Japan

Eisai and Biogen’s anti-amyloid drug is still undergoing regulatory reviews in the EU, U.K. and elsewhere.

By Ned Pagliarulo • Sept. 25, 2023

Driving innovation to benefit people living with MS

A holistic approach to R&D is key to support MS patients throughout their treatment journey.

By Pat Vallano, Ph.D., Head of Innovative Programs, R&D, Viatris • Sept. 25, 2023

AstraZeneca and Daiichi’s next cancer medicine scores in breast tumors

Results show that the medicine helped patients who progressed on earlier-line treatments live longer than those receiving chemotherapy without their disease getting worse, according to a Friday announcement.

By Jonathan Gardner • Sept. 22, 2023

Alvotech gets new FDA review for Humira biosimilar

The regulator has twice rejected Alvotech’s copycat drug due to manufacturing issues with a plant in Europe.

By Jonathan Gardner • Sept. 20, 2023

PBMs, PhRMA trade blame over drug costs in House hearing

Pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA pointed fingers over problems in the prescription supply chain during the House committee's second hearing on the PBM industry.

By Rebecca Pifer • Sept. 19, 2023

Novartis cancels Beigene partnership as cancer drug gains EU approval

The terminated deal leaves Novartis without a PD-1 inhibitor nine years after Merck’s Keytruda won its first approval.

By Jonathan Gardner • Sept. 19, 2023

FTC takes aim at pharma patent tactics used to block generics

The antitrust regulator is examining what it describes as abuse of the FDA “Orange Book” — another step in its scrutiny of pharma business practices.

By Jonathan Gardner • Sept. 15, 2023

FDA approves updated COVID boosters from Pfizer, Moderna

Pfizer and Moderna, which have seen slowing demand for their coronavirus vaccines, expect their reformulated shots will soon be available in the U.S.

By Delilah Alvarado • Sept. 11, 2023

Novartis stops work on gene therapy acquired in Gyroscope deal

The decision follows a review by a trial monitoring committee, which concluded data for the geographic atrophy treatment didn't support further development.

By Delilah Alvarado • Sept. 11, 2023

Manufacturing delays under-the-skin Tecentriq shot in US

Roche says it won’t be able to launch the subcutaneous version of the drug until 2024 as it works with the FDA on manufacturing updates.

By Jonathan Gardner • Sept. 8, 2023

Moderna says updated COVID shot likely to protect against worrisome variant

The findings add to early evidence showing a heavily mutated variant called BA.2.86, which is growing in prevalence, may not be as evasive as scientists once feared.

By Delilah Alvarado • Sept. 6, 2023

Roche claims study success for targeted drug in early lung cancer

The Swiss pharma said, without details, that it observed “unprecedented” results that could make Alecensa the first treatment specifically available after surgery for ALK-positive lung tumors.

By Ben Fidler • Sept. 1, 2023

Sanofi appoints a venture investor to R&D head as executive team expands

Houman Ashrafian, currently a scientific advisor at SV Health Investors, will fill the role left by John Reed, who oversaw the transformation of research and development during his five years at Sanofi.

By Jacob Bell • Aug. 31, 2023

The intelligent content ecosystem is here. Is your organization ready?

Is pharma up to the challenge of delivering the personalized and contextual experiences doctors have come to expect? Too often, the answer is no.

By Saby Mitra, Global Digital Customer Experience Practice Leader at ZS • Aug. 28, 2023

Roche’s surprise study results spur new optimism for TIGIT drugs

Data inadvertently published from a closely watched lung cancer study suggest a drug blocking the protein TIGIT may help extend survival, a finding that boosted shares of other developers. 

By Jonathan Gardner • Aug. 23, 2023